Get started
Author

Chieh-I Chen

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
2021 · Ahmet Sezer, Saadettin Kilickap, et al. · The Lancet · 813
Global Prevalence and Economic Burden of Urgency Urinary Incontinence: A Systematic Review
2013 · Ian Milsom, Karin S. Coyne, et al. · European Urology · 466
Economic Burden of Urgency Urinary Incontinence in the United States: A Systematic Review
2014 · Karin S. Coyne, Alan Wein, et al. · Journal of Managed Care Pharmacy · 316
PDF
The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: Results from OAB‐POLL
2012 · Karin S. Coyne, Chris C. Sexton, et al. · Neurourology and Urodynamics · 266
PDF
Prevalence and Effect on Health‐Related Quality of Life of Overactive Bladder in Older Americans: Results from the Epidemiology of Lower Urinary Tract Symptoms Study
2011 · Chris C. Sexton, Karin S. Coyne, et al. · Journal of the American Geriatrics Society · 169
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis
2021 · Danny Rischin, Nikhil I Khushalani, et al. · Journal for ImmunoTherapy of Cancer · 119
PDF
Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma
2025 · Danny Rischin, Sandro Porceddu, et al. · New England Journal of Medicine · 109
Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial
2016 · Vibeke Strand, Mark Kosinski, et al. · Arthritis Research & Therapy · 70
PDF
Burden of rheumatoid arthritis among US Medicare population: co-morbidities, health-care resource utilization and costs
2018 · Chieh-I Chen, Li Wang, et al. · Rheumatology Advances in Practice · 68
PDF
Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy
2017 · Wenhui Wei, Keith Knapp, et al. · Advances in Therapy · 63
PDF
Comparative Efficacy of Cemiplimab Versus Other Systemic Treatments for Advanced Cutaneous Squamous Cell Carcinoma
2020 · Sam Keeping, Yingxin Xu, et al. · Future Oncology · 51
Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis
2018 · Vibeke Strand, Laure Gossec, et al. · Arthritis Research & Therapy · 46
PDF
The Impact of OAB on Physical Activity in the United States: Results from OAB-POLL
2013 · Karin S. Coyne, Chris C. Sexton, et al. · Urology · 46
Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors
2017 · Vibeke Strand, Matthew Reaney, et al. · RMD Open · 44
PDF
CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma
2020 · Michael R Migden, Sunandana Chandra, et al. · Future Oncology · 39
Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA
2017 · Benjamin Chastek, Chieh-I Chen, et al. · Advances in Therapy · 39
PDF
EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer
2022 · Ana Oaknin, Bradley J. Monk, et al. · European Journal of Cancer · 38
Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50%
2021 · Andreas Kuznik, Caitlin Smare, et al. · Value in Health · 37
Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis
2016 · Benjamin Chastek, Laura K. Becker, et al. · Journal of Medical Economics · 37
PDF
Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis
2021 · Gerasimos Konidaris, Eleanor Paul, et al. · Value in Health · 35
PDF
Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medication
2016 · Machaon Bonafede, Jeffrey Curtis, et al. · ClinicoEconomics and Outcomes Research · 31
PDF
Recent trends in exposure to secondhand smoke in the United States population
2010 · Chieh-I Chen, Tanya Burton, et al. · BMC Public Health · 29
PDF
An Open-label Pilot Trial of Ibandronate for Complex Regional Pain Syndrome
2008 · Brenda Breuer, Marco Pappagallo, et al. · Clinical Journal of Pain · 29
Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses
2019 · Ernest Choy, Nick Freemantle, et al. · RMD Open · 27
PDF
Effects of Copayment on Initiation of Smoking Cessation Pharmacotherapy: An Analysis of Varenicline Reversed Claims
2011 · Feng Zeng, Chieh-I. Chen, et al. · Clinical Therapeutics · 25
Works count: 95
Citation count: 3,317
H-index: 25
I10-index: 37
Year
Topic
Type